<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456935</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_301</org_study_id>
    <nct_id>NCT02456935</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis</brief_title>
  <official_title>A Double-blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of CJ-12420, once daily (QD),
      compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA)
      classification grades A to D at Week 8
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, active controlled, phase 3 study. Subjects will be
      randomly assigned to one of the two treatment groups (CJ-12420 100 mg or esomeprazole 40 mg).

      All subjects will be asked to take two tablets at the same time each day throughout the
      study, and also all subjects will be asked to record daytime and nighttime symptom in a
      subject diary on a daily basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative healing rate of erosive esophagitis at 8-week</measure>
    <time_frame>8 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing rate of erosive esophagitis at 4-week</measure>
    <time_frame>4 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom assessment by subject diary and questionnaire</measure>
    <time_frame>4 week or 8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">280</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>CJ-12420 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 100 mg QD</intervention_name>
    <description>CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.</description>
    <arm_group_label>CJ-12420 100 mg QD</arm_group_label>
    <other_name>Not yet decided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40 mg QD</intervention_name>
    <description>Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.</description>
    <arm_group_label>Esomeprazole 40 mg QD</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 20 and 70 years

          2. Subjects who had experienced heartburn and regurgitation within 7 days before visit 1.
             Entry into study also required that patients had experienced at least mild upper
             gastrointestinal symptoms on at least 2 days/week or at least moderate upper
             gastrointestinal symptoms on at least 1 day/week

          3. Endoscopically confirmed erosive esophagitis as defined by LA Classification Grading
             System (A-D) within 14 days prior to randomization

          4. Subjects who is able to understand and follow the instructions and is willing to
             participate throughout the entire study

          5. Subjects who voluntarily signed written informed consent form

          6. Subjects who agreed to use medically acceptable contraceptives during the period of
             study.

        Exclusion Criteria:

          1. Subjects who cannot undergo EGD

          2. Subjects who have esophageal stenosis, ulcer stenosis, gastroesophageal varices,
             Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding or malignant
             tumor confirmed by EGD

          3. Subjects who have warning symptoms of malignant gastrointestinal tract such as
             odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool

          4. Subjects with eosinophilic esophagitis

          5. Subjects diagnosed with primary esophageal motility disorder, IBS, IBD, etc. or with
             suspected IBS in the last 3 months

          6. Subjects who have a history of gastric acid suppression surgery or upper
             gastrointestinal, esophageal surgery

          7. Pregnant or lactating women

          8. Subjects with a history of clinically significant hepatic, renal, cardiovascular,
             respiratory, endocrine and CNS system disorder

          9. Subjects with a history of hypersensitivity to the active ingredient or excipients of
             the study drug, etc.

         10. Subjects who participated in the other clinical trial within 4 weeks prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyun Chae Jung, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

